CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for COSCIENS Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

COSCIENS Biopharma Inc
C/O Norton Rose Fulbright Canada Llp
222 Bay Street, Suite 3000,
Phone: (418) 652-8525p:418 652-8525 TORONTO, ON  M5K 1E7  Canada Ticker: CSCICSCI
Business Summary
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
(Source: 10KSB40)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Ronald W.Miller 6/3/2024 6/3/2024
President, Chief Executive Officer, Director Gilles R.Gagnon 6/3/2024 9/26/2000
Chief Financial Officer, Senior Vice President, Director GiulianoLa Fratta 6/3/2024 1/24/2022
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Ceapro Inc 7824 51 Ave NW EDMONTON AB Canada

Business Names
Business Name
Aeterna Zentaris GmbH
Aeterna Zentaris, Inc.
AEZ
5 additional Business Names available in full report.

General Information
Number of Employees: 21 (As of 12/31/2022)
Outstanding Shares: 3,758,857 (As of 11/20/2024)
Shareholders: 234
Stock Exchange: TSE
Federal Tax Id: 000000000
Fax Number: (418) 948-9191


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024